LIN — Linde plc

Q2 2026 adjusted EPS of $4.50 edged consensus, but full-year guidance of $17.70-$17.90 came in a touch below the street's $17.93, and adjusted operating margin fell 60 bps YoY to 29.5%. The stock fell ~5-6% post-release. The analyst base is still firmly Buy (25 buy vs 3 hold, avg target ~$566), so the mood is cautious-neutral rather than bearish.

Revenue growth is clearly accelerating: quarterly revenue went from $8.11B in Q1 2025 to a record $9.29B in Q2 2026, with YoY growth climbing from ~2.8% in Q2 2025 to ~9.3% in Q2 2026. GAAP diluted EPS rose ~11% YoY to $4.15, and the FY2026 guide implies strong continued EPS growth. Reported operating margins are noisy—Q4 2025 was only 23.0% and Q1 2026 spiked to 37.2%, likely reflecting charges and one-off items—so the cleaner signal is adjusted operating margin down 60 bps YoY to 29.5%. The trend is accelerating top-line growth with modest near-term margin compression, not deterioration.

Fair to slightly rich. As of 2026-08-27, TTM P/E is 31.2x, below its 5-year average of 35.6x, but P/S of 6.33x is above the 5-year average of 5.75x and PEG is ~3.1x. On FY2026 consensus EPS of $17.88, the forward P/E is a little under 27x—a full quality premium for a company growing EPS at high single digits to low double digits. It is not cheap, but it is not historically overextended either.

The $485 price is paying ~27x forward earnings for a steady compounder, so it already capitalizes a lot of Linde's quality. Upside requires the record $8.1B electronics/backlog to convert into margin recovery above 30%; downside risk is an EPS guidance reset or persistent FCF/margin compression, which would de-rate a premium multiple. A better tactical entry would be a pullback toward the $450-$470 zone, where the valuation cushion is more meaningful.

As of 2026-08-27, RSI is 44.5, price is +0.1% vs the 20-day, -3.9% vs the 50-day, and +1.4% vs the 200-day. That is a pullback within a longer-term uptrend, with no oversold or breakout signal. Entry timing would improve on a reclaim of the 50-day or an RSI below ~35.

• Take-or-pay contracts and price indexation protect revenue, but cost inflation in Q2 2026 temporarily outpaced pricing, compressing adjusted operating margins by 60 bps YoY.
• The electronics/semiconductor capex cycle is a major tailwind: the sale-of-gas backlog hit a record $8.1B, anchored by a ~$1B ultra-high-purity gas win for advanced U.S. semiconductor fabs.
• Clean hydrogen and carbon capture projects are long-dated optionality, but timing has slipped (material Woodside-related contributions push into 2027), limiting near-term earnings impact.
• Higher interest rates pressure premium multiples; Linde's defensive cash flows and 34-year dividend growth streak make it more attractive if rates fall.
• U.S. home healthcare and parts of the chemicals cycle are structural/cyclical drags, partially offsetting strength in electronics and North America/APAC manufacturing.

• Q3 2026 earnings in late October: evidence that adjusted operating margins return above 30% and that FY2026 guidance is achieved at the high end or raised.
• Conversion of the record $8.1B sale-of-gas backlog, especially the $1B semiconductor win, into revenue and operating cash flow.
• Fed easing or lower long-term rates, which could re-rate high-quality defensive compounders like Linde.

• Persistent margin compression if cost inflation and the U.S. home healthcare drag continue to outpace pricing and productivity.
• Elevated capex (Q2 2026 capex +14.4% YoY) is suppressing FCF ($833M in Q2, down ~13% YoY); current ratio is 0.88, so the balance-sheet buffer is thinner than the quality label implies.
• Valuation de-rating risk: at ~27x forward earnings, the market already pays for perfection; any guidance shortfall or macro downturn could produce a meaningful multiple contraction.
• Cyclical end-markets (chemicals, metals, manufacturing) and potential delays in clean-energy or backlog project execution could slow the acceleration.

Linde is a best-in-class industrial gas franchise with accelerating revenue, a record project backlog, and genuine pricing power. The catch is price: at ~27x forward earnings and with near-term margin and free-cash-flow headwinds, the risk-reward is balanced rather than compelling. This is a high-quality business to own, but not an obvious bargain at the 2026-08-27 quote; I'd look for a better entry or confirmation that margins are re-expanding.

Applied a justified forward P/E of ~30.5x to FY2026 consensus EPS of $17.88—a slight discount to the 5-year average trailing P/E of 35.6x to reflect current margin/FCF pressure, but above the current ~27x forward multiple to reflect Linde's record backlog, accelerating revenue, and defensive cash flows.